Expression of PD1, ICOS, and CD38 were similar between COVID-19-naïve individuals with PAD syndromes and healthy donors at day 7 to 28 following vaccination, suggesting there was no defect in CD4+ T cell activation in most individuals with PAD syndromes (Figures 7C–E). This evidence concerns the gene CD38 and COVID-19.